These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10673106)

  • 1. RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.
    Peyman A; Wehner V; Knolle J; Stilz HU; Breipohl G; Scheunemann KH; Carniato D; Ruxer JM; Gourvest JF; Gadek TR; Bodary S
    Bioorg Med Chem Lett; 2000 Jan; 10(2):179-82. PubMed ID: 10673106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
    Stilz HU; Guba W; Jablonka B; Just M; Klingler O; König W; Wehner V; Zoller G
    J Med Chem; 2001 Apr; 44(8):1158-76. PubMed ID: 11312916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIb beta3 and alpha(v) beta3 integrins and expression of ligand-induced binding site.
    Marcinkiewicz C; Vijay-Kumar S; McLane MA; Niewiarowski S
    Blood; 1997 Aug; 90(4):1565-75. PubMed ID: 9269775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
    Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of the sixth immunoglobulin-like domain of mouse neural cell adhesion molecule L1 and its interactions with alpha(v)beta3, alpha(IIb)beta3, and alpha5beta1 integrins.
    Blaess S; Kammerer RA; Hall H
    J Neurochem; 1998 Dec; 71(6):2615-25. PubMed ID: 9832163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha(v)beta(3) Antagonists based on a central thiophene scaffold.
    Peyman A; Scheunemann K; Will DW; Knolle J; Wehner V; Breipohl G; Stilz HU; Carniato D; Ruxer J; Gourvest J; Auberval M; Doucet B; Baron R; Gaillard M; Gadek TR; Bodary S
    Bioorg Med Chem Lett; 2001 Aug; 11(15):2011-5. PubMed ID: 11454469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cluster of basic amino acid residues in the gamma370-381 sequence of fibrinogen comprises a binding site for platelet integrin alpha(IIb)beta3 (glycoprotein IIb/IIIa).
    Podolnikova NP; Gorkun OV; Loreth RM; Yee VC; Lord ST; Ugarova TP
    Biochemistry; 2005 Dec; 44(51):16920-30. PubMed ID: 16363805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH; Sassoli PM; Jordan RE; Nakada MT
    Circulation; 1998 Sep; 98(11):1085-91. PubMed ID: 9736595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of (2S,3S) and (2S,3R) beta-methyl aspartic acid into RGD-containing peptides.
    Schabbert S; Pierschbacher MD; Mattern RH; Goodman M
    Bioorg Med Chem; 2002 Oct; 10(10):3331-7. PubMed ID: 12150880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RGD-mutants of B-lymphotropic polyomavirus capsids specifically bind to alpha(v)beta3 integrin.
    Langner J; Neumann B; Goodman SL; Pawlita M
    Arch Virol; 2004 Oct; 149(10):1877-96. PubMed ID: 15290355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins.
    McLane MA; Vijay-Kumar S; Marcinkiewicz C; Calvete JJ; Niewiarowski S
    FEBS Lett; 1996 Aug; 391(1-2):139-43. PubMed ID: 8706902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential antagonism of the interactions of the integrin alpha IIb beta 3 with immobilized glycoprotein ligands by snake-venom RGD (Arg-Gly-Asp) proteins. Evidence supporting a functional role for the amino acid residues flanking the tripeptide RGD in determining the inhibitory properties of snake-venom RGD proteins.
    Lu X; Williams JA; Deadman JJ; Salmon GP; Kakkar VV; Wilkinson JM; Baruch D; Authi KS; Rahman S
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):929-36. PubMed ID: 7529494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.
    Sulyok GA; Gibson C; Goodman SL; Hölzemann G; Wiesner M; Kessler H
    J Med Chem; 2001 Jun; 44(12):1938-50. PubMed ID: 11384239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S; Lu X; Kakkar VV; Authi KS
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction.
    Gawaz M; Neumann FJ; Dickfeld T; Reininger A; Adelsberger H; Gebhardt A; Schömig A
    Circulation; 1997 Sep; 96(6):1809-18. PubMed ID: 9323066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Basis for the Binding of RGD- and AGDV-Peptides to the Platelet Integrin αIIbβ3.
    Kononova O; Litvinov RI; Blokhin DS; Klochkov VV; Weisel JW; Bennett JS; Barsegov V
    Biochemistry; 2017 Apr; 56(13):1932-1942. PubMed ID: 28277676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
    Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
    Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3).
    Batt DG; Petraitis JJ; Houghton GC; Modi DP; Cain GA; Corjay MH; Mousa SA; Bouchard PJ; Forsythe MS; Harlow PP; Barbera FA; Spitz SM; Wexler RR; Jadhav PK
    J Med Chem; 2000 Jan; 43(1):41-58. PubMed ID: 10633037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.